Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

Q4 2024 Management View CEO Thomas Schinecker emphasized that 2024 was an "excellent year," with overall group sales growing ...

Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...

We're going to check out a few of the best picks from our screener tool. Overview: Roche Bobois S.A. is a global company involved in the design and distribution of furniture, with a market cap of ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be ...